scholarly journals Cytotoxic effect in vivo of selected chemotherapeutic agents on synchronized murine fibrosarcoma cells

1980 ◽  
Vol 42 (5) ◽  
pp. 677-683 ◽  
Author(s):  
D J Grdina ◽  
C P Sigdestad ◽  
L J Peters
Keyword(s):  
Cytotoxic Effect ◽  
Chemotherapeutic Agents ◽  
Fibrosarcoma Cells ◽  
Murine Fibrosarcoma

scholarly journals Cytotoxic effect of Montivipera bornmuelleri’s venom on cancer cell lines: in vitro and in vivo studies

PeerJ ◽  
2020 ◽  
Vol 8 ◽  
pp. e9909
Author(s):  
Carol Haddoub ◽  
Mohamad Rima ◽  
Sandrine Heurtebise ◽  
Myriam Lawand ◽  
Dania Jundi ◽  
...  
Keyword(s):  
Tumor Growth ◽  
Cell Lines ◽  
Cytotoxic Effect ◽  
In Vivo Studies ◽  
Dependent Manner ◽  
In Vivo Testing ◽  
Murine Fibrosarcoma ◽  
Dose Dependent

Background Montivipera bornmuelleri’s venom has shown immunomodulation of cytokines release in mice and selective cytotoxicity on cancer cells in a dose-dependent manner, highlighting an anticancer potential. Here, we extend these findings by elucidating the sensitivity of murine B16 skin melanoma and 3-MCA-induced murine fibrosarcoma cell lines to M. bornmuelleri’s venom and its effect on tumor growth in vivo. Methods The toxicity of the venom on B16 and MCA cells was assessed using flow cytometry and xCELLigence assays. For in vivo testing, tumor growth was followed in mice after intratumoral venom injection. Results The venom toxicity showed a dose-dependent cell death on both B16 and MCA cells. Interestingly, overexpression of ovalbumin increased the sensitivity of the cells to the venom. However, the venom was not able to eradicate induced-tumor growth when injected at 100 µg/kg. Our study demonstrates a cytotoxic effect of M. bornmuelleri’s venom in vitro which, however, does not translate to an anticancer action in vivo.

Cytotoxic effect in vitro and tumour volume reduction in vivo induced by chemotherapeutic agents

1974 ◽  
Vol 10 (10) ◽  
pp. 667-671 ◽  
Author(s):  
L. Morasca ◽  
G. Balconi ◽  
E. Erba ◽  
P. Lelieveld ◽  
L.M. Van Putten
Keyword(s):  
Cytotoxic Effect ◽  
Tumour Volume ◽  
Chemotherapeutic Agents ◽  
Volume Reduction

Cytotoxic effect of adriamycin in vivo on synchronized murine fibrosarcoma cellst

1979 ◽  
Vol 5 (8) ◽  
pp. 1305-1308 ◽  
Author(s):  
David J. Grdina ◽  
Curtis P. Sigdestad ◽  
Jean A. Jovonovich
Keyword(s):  
Cytotoxic Effect ◽  
Murine Fibrosarcoma

Przeciwnowotworowe działanie składników propolisu. Cz. 2. Związki flawonoidowe

2020 ◽  
Vol 21 (4) ◽  
Author(s):  
Elżbieta Hołderna-Kędzia
Keyword(s):  
Cytotoxic Effect ◽  
Pharmacological Properties ◽  
Flavonoid Compounds ◽  
Anti Cancer ◽  
Fibrosarcoma Cells ◽  
Ic50 Values ◽  
Human Fibrosarcoma Cells ◽  
A549 Lung

The paper presents a review of research on the anticancerogenic activity of flavonoid compounds and their prenylated derivatives occurring in the propolis. In addition to the numerous biological and pharmacological properties of flavonoids, they also have a cytotoxic effect. The presented studies of flavonoids isolated from propolis fractions of various origins were carried out in vitro and in vivo against various human and animal cancer cell lines, e.g. HT-1080 human fibrosarcoma cells, A549 lung adenocarcinoma and Hela cervix, murine L5-26 colon carcinoma and B16-BL6 melanoma, and others. The obtained cytotoxic activity of flavonoid compounds and their prenylated derivatives as IC50 values was in the range of 3.4-10.0 μg/ml, while the ED50 values were in the range of 2.3-205.0 μg/ml. Flavonoids have a multidirectional effect on cancer cells: antioxidant, antiproliferative, blocking the cell cycle, inhibiting angiogenesis, inducing apoptosis, and inactivating carcinogens and reducing the resistance of anti-cancer drugs.

scholarly journals Trientine, a Copper-Chelating Agent, Induced Apoptosis in Murine Fibrosarcoma Cells In Vivo and In Vitro

2007 ◽  
Vol 69 (2) ◽  
pp. 137-142 ◽  
Author(s):  
Masanobu HAYASHI ◽  
Hide NISHIYA ◽  
Toshiaki CHIBA ◽  
Daiji ENDOH ◽  
Yasuhiro KON ◽  
...  
Keyword(s):  
Chelating Agent ◽  
Fibrosarcoma Cells ◽  
Murine Fibrosarcoma ◽  
Induced Apoptosis

scholarly journals The synergistic proapoptotic effect of PARP-1 and HDAC inhibition in cutaneous T-cell lymphoma is mediated via Blimp-1

2020 ◽  
Vol 4 (19) ◽  
pp. 4788-4797
Author(s):  
Oleg Kruglov ◽  
Xuesong Wu ◽  
Sam T. Hwang ◽  
Oleg E. Akilov
Keyword(s):  
T Cell ◽  
Cytotoxic Effect ◽  
Cell Lymphoma ◽  
Complementation Group ◽  
Chemotherapeutic Agents ◽  
T Cell Lymphoma ◽  
Cutaneous T Cell Lymphoma ◽  
M Cell ◽  
Parp 1

Abstract The therapy of advanced mycosis fungoides (MF) presents a therapeutic challenge, and the search for new therapeutic targets is ongoing. Poly(ADP-ribose) polymerase 1 was shown to be upregulated in patients with advanced MF and could be druggable by a new class of chemotherapeutic agents, PARP-1 inhibitors, which are already in clinical trials for other malignancies; however, the role of PARP-1 inhibitors in MF has never been established. We examined the efficacy of talazoparib in the murine model of cutaneous T-cell lymphoma. The cytotoxic effect of talazoparib on Moloney MuLV-induced T-cell lymphoma (MBL2) cells was a result of G2/M cell cycle arrest via the upregulation of p53. The in vivo experiments confirmed the clinical impact of talazoparib on MF tumors. When talazoparib was combined with the histone deacetylase (HDAC) inhibitor, romidepsin, the cytotoxic effect was synergized via downregulation of the DNA-repair genes Fanconianemia complementation group A (FANCA), Fanconi anemia complementation group D2 (FANCD2), and DNA topoisomerase II binding protein 1(TOPBP1)and stimulation of apoptosis via Blimp-1 (PRDM1)/Bax axis. Romidepsin increased the expression of IRF8 and Bcl-6, leading to upregulation of Blimp1and Bax; whereas talazoparib upregulated Blimp-1 and Bax via upregulation of interferon regulatory factor 4 (IRF4), leading to cleavage of caspases 6 and 7. Thus, a combination of talazoparib with romidepsin demonstrated the synergistic antilymphoma effect and warranted further investigation in a clinical trial.

KIDNEY INJURY IN CANCER THERAPY

2018 ◽  
Vol 22 (5) ◽  
pp. 17-24 ◽  
Author(s):  
E. V. Burnasheva ◽  
Y. V. Shatokhin ◽  
I. V. Snezhko ◽  
A. A. Matsuga
Keyword(s):  
Risk Factors ◽  
Acute Kidney Injury ◽  
Cancer Therapy ◽  
Cancer Patients ◽  
Cytotoxic Effect ◽  
Tumor Lysis Syndrome ◽  
Kidney Injury ◽  
Chemotherapeutic Agents ◽  
Oxygen Intermediates ◽  
Circulating Blood Volume

Кidney injury is a frequent and significant complication of cancer and cancer therapy. The kidneys are susceptible to injury from malignant infiltration, damage by metabolites of malignant cells, glomerular  injury, nephrotoxic drugs including chemotherapeutic agents. Also  bone marrow transplantation complications, infections with immune  suppression (including septicemia), tumor lysis syndrome should be  taken into account. Chemotherapeutic agents are a common cause  of acute kidney injury but can potentially lead to chronic kidney  disease development in cancer patients. This article summarizes risk  factors of acute kidney injury in cancer patients. Risk factors are  divided into two groups. The systemic are decrease of total  circulating blood volume, infiltration of kidney tissue by tumor cells,  dysproteinemia, electrolyte disturbances. The local (renal) risk  factors are microcirculation disturbances, drugs biotransformation  with formation of reactive oxygen intermediates, high concentration of nephrotoxic agents in proximal tubules and its  sensitivity to ischemia. Drug-related risk factors include: drugs  combination with cytotoxic effect high doses long term use necessity, direct cytotoxic effect of not only chemotherapeutic agents but also its metabolites, mean solubility forming intratubular  precipitates. Early diagnosis, timely prevention and treatment of  these complications provide significantly improve nononcologic results of treatment.

scholarly journals Glycosphingolipid expression on murine L1-fibrosarcoma cells: analysis of clonal in vivo and in vitro selected sublines with different lung colonisation potential

1990 ◽  
Vol 61 (6) ◽  
pp. 813-820 ◽  
Author(s):  
F-G Hanisch ◽  
J Sölter ◽  
V Jansen ◽  
A Lochner ◽  
J Peter-Katalinic ◽  
...  
Keyword(s):  
Fibrosarcoma Cells
Sign in / Sign up

Export Citation Format

Share Document